FT836

Other Medications

1 Clinical Trials

Description

FT836 is an experimental medication currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being investigated to see how safe it is and what the best dose might be when given alone or in combination with other cancer treatments like chemotherapy (paclitaxel) and monoclonal antibodies (trastuzumab or cetuximab). This is a Phase 1 trial, which means the main goal is to assess safety and find the right dose for further studies, not primarily to see if it shrinks tumors. The trial is currently recruiting participants.

Mechanism of Action

FT836 is being studied as a potential cancer treatment. The specific way it works (its mechanism of action) is still being investigated in clinical trials. It is designed to be used in combination with other therapies.

Side Effects

Because FT836 is an experimental drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of this Phase 1 trial is to determine the safety and tolerability of FT836. Information about specific side effects will become clearer as the trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07216105 Phase 1
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
United States

Quick Info

CategoryOther Medications
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
781 trials
Leucovorin
Other Medications
641 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.